Total trials
161
Active
84
Phase 3
35
Total enrollment
33,234
Pipeline matrix
Showing 40 of 92 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| AK112 | — | — | — | 31 | |||
| AK104 | — | — | 32 | ||||
| Paclitaxel | — | — | — | — | 13 | ||
| Cadonilimab | — | — | — | 10 | |||
| Carboplatin | — | — | — | 13 | |||
| Oxaliplatin | — | — | — | — | 8 | ||
| Cisplatin | — | — | — | — | 7 | ||
| Ivonescimab | — | — | — | 5 | |||
| Pemetrexed | — | — | — | — | 6 | ||
| Capecitabine | — | — | — | — | 5 | ||
| Irinotecan | — | — | — | — | 4 | ||
| Lenvatinib | — | — | — | — | 4 | ||
| Penpulimab | — | — | — | — | 3 | ||
| Bevacizumab | — | — | — | — | 3 | ||
| Nab-paclitaxel | — | — | — | — | 2 | ||
| Calcium Folinate | — | — | — | — | 2 | ||
| Leucovorin and 5-FU | — | — | — | — | — | 1 | |
| CAPOX regimen | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 1 | |
| Tislelizumab | — | — | — | — | — | 1 | |
| AK112, Carboplatin, Paxlitaxel | — | — | — | — | — | 1 | |
| Tislelizumab, Carboplatin, Paxlitaxel | — | — | — | — | — | 1 | |
| 5- Fluorouracil | — | — | — | — | — | 1 | |
| Ivonescimab, docetaxel | — | — | — | — | — | 1 | |
| AK117 in combination with AK112 | — | — | — | — | — | 1 | |
| Sugemalimab | — | — | — | — | — | 1 | |
| Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine | — | — | — | — | — | 1 | |
| Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine | — | — | — | — | — | 1 | |
| Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine | — | — | — | — | — | 1 | |
| pulocimab | — | — | — | — | — | 1 | |
| AK112, Gemcitabine, Cisplatin | — | — | — | — | — | 1 | |
| Durvalumab, Gemcitabine, Cisplatin | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| SOX chemotherapy | — | — | — | — | — | 1 | |
| AK117 | — | — | — | — | 14 | ||
| AK146D1 for | — | — | — | — | 5 | ||
| Docetaxel | — | — | — | — | — | 6 | |
| Azacitidine | — | — | — | — | — | 4 | |
| AK138D1 | — | — | — | — | 4 | ||
| Chemotherapy | — | — | — | — | — | 4 |
52 more active programs hidden
Next readouts
- 2023-03-10
- 2023-08-15
- 2024-01-29
- 2024-11-30
- 2025-02-28
- 2025-04-30
- 2025-06
- 2025-06-30
- 2025-08-05
- 2025-08-18
Top conditions
- Hepatocellular Carcinoma8
- Atopic Dermatitis8
- Advanced Solid Tumors7
- Advanced Malignant Tumors6
- Psoriasis5
- Solid Tumor4
- Nasopharyngeal Carcinoma4
- Hyperlipidemia3
Frequently asked questions about Akeso
- How many clinical trials does Akeso have on ClinicalTrials.gov?
- Akeso is listed as the lead sponsor on 161 clinical trials in ClinicalTrials.gov, 84 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Akeso's trials are in Phase 3?
- 35 of Akeso's trials are in Phase 3, spread across 92 active drug programs.
- What therapeutic areas does Akeso focus on?
- Akeso's most-studied conditions on ClinicalTrials.gov are Hepatocellular Carcinoma, Atopic Dermatitis, Advanced Solid Tumors, Advanced Malignant Tumors, Psoriasis.
- When are Akeso's next clinical trial readouts?
- Akeso has 10 upcoming primary-completion readouts tracked here; the soonest is “Phase 3 Clinical Study of AK112 for NSCLC Patients”, expected around 2023-03-10.